Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis

OBJECTIVE: Lenvatinib and sorafenib are first-line oral multikinase inhibitors approved for the treatment of advanced hepatocellular carcinoma (HCC). However, the choice of the primary therapeutic agent among these two remains controversial. This meta-analysis aimed to estimate the efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jia, Gao, Benjian, Lin, Zhiyu, Fan, Hua, Ma, Wen, Yu, Danfei, Yang, Qian, Tian, Jing, Yang, Xiaoli, Li, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814719/
https://www.ncbi.nlm.nih.gov/pubmed/36620586
http://dx.doi.org/10.3389/fonc.2022.1010726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814719/
https://www.ncbi.nlm.nih.gov/pubmed/36620586
http://dx.doi.org/10.3389/fonc.2022.1010726

Ejemplares similares